HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation.

Abstract
We investigated changes in receptor-binding domain IgG and neutralizing antibodies against the omicron and delta variants, vs the wild-type virus, in response to a fourth BNT162b2 dose in 90 heart transplant (HT) recipients. The fourth dose induced anti-RBD IgG antibodies and a higher neutralization efficiency against the wild-type virus and the variants; however, neutralization efficiency against the omicron variant was lower than that against the delta variant (the latter demonstrating efficacy similar to that against the wild-type virus). Notably, while IgG anti-RBD antibodies were detectable in >80% of the HT recipients, only about half demonstrated neutralization efficiency against the omicron variant. A SARS-CoV-2-specific-T-cell response following the fourth dose was evident in the majority of transplant recipients. Boosting vulnerable groups improves antibody responses (including neutralizing responses) and cellular immunity, but the incomplete immunological response, particularly for omicron, suggests continued preventive measures and optimization of vaccination strategies that elicit strong, and long-lasting immune responses, in this high-risk population, should remain a priority.
AuthorsYael Peled, Arnon Afek, Ital Nemet, Galia Rahav, Ehud Raanani, Jignesh K Patel, Michal Mandelboim
JournalThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (J Heart Lung Transplant) Vol. 41 Issue 9 Pg. 1210-1213 (09 2022) ISSN: 1557-3117 [Electronic] United States
PMID35794051 (Publication Type: Journal Article)
CopyrightCopyright © 2022 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 Vaccines
  • Immunoglobulin G
  • BNT162 Vaccine
Topics
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • BNT162 Vaccine (administration & dosage, adverse effects)
  • COVID-19 (prevention & control)
  • COVID-19 Vaccines
  • Heart Transplantation
  • Humans
  • Immunoglobulin G
  • Neutralization Tests
  • SARS-CoV-2

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: